Please ensure Javascript is enabled for purposes of website accessibility

Why DermTech Stock Gained 26% Last Month

By Jeremy Bowman - Updated Feb 8, 2021 at 4:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor excitement mounted around the skin-care detection specialist.

What happened

Shares of DermTech (DMTK 9.17%), a biotech company focused on skin-cancer testing, gained last month as the company continued to attract positive analyst attention and build on momentum from last December. Back then, the company announced results from a TRUST study that showed that its Pigmented Lesion Assay (PLA), its non-invasive skin-cancer test, was 99% accurate when it showed negative results.

According to data from S&P Global Market Intelligence, the stock finished January up 26%. The chart below shows the stock's trajectory for the month.

DMTK Chart

DMTK data by YCharts.

So what

There was not much fundamental news out on DermTech, but attention to the stock is clearly increasing, with trading volumes up substantially following the announcement in December. 

The DermTech melanoma-testing patch

Image source: DermTech.

The stock jumped 20% over a two-day span after it announced and then priced a secondary stock offering of 4.2 million shares at $29.50, less than what the stock was trading for at that time. The company expects to bring in $125 million in gross proceeds from the offering, which it will use to fund further commercialization of its clinical tests and accelerate pipeline development. This elicited cheers from investors.

Though the stock gave back some of those gains on Jan. 8, it started rallying the following week with the help of a bullish analyst note from Lake Street, which raised its price target from $24 to $52. That same day, the company announced that PLA, its skin-care testing patch, had received a recommendation from the National Comprehensive Cancer Network.

DermTech climbed again in the third week of January as Craig-Hallum raised its price target from $23 to $49 and Oppenheimer initiated coverage on the stock with a buy rating and a price target of $53.

Now what

It's still early in February, but DermTech shares are already up 40% this month through Feb. 8, showing that investor excitement about the stock is continuing to build. Considering that the market for such melanoma testing is estimated to be worth about $10 billion, according to DermTech, and the company is only valued at $1.4 billion, the healthcare stock appears to have more upside potential -- and that doesn't include the impact of future products. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DermTech, Inc. Stock Quote
DermTech, Inc.
$7.14 (9.17%) $0.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.